Abstract：
Shenqi pill (SQP) can be used to treat various kidney related diseases, but its exact mechanism of action remains unclear. We intended to analyze the role and mechanism of SQP on renal interstitial fibrosis (RIF).
After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.
SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).
Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.
After performing unilateral ureteral obstruction (UUO) surgery following the Institutional Animal Care and Use Committee guidelines, all rats were assigned into the sham group, UUO group, UUO + SQP 1.5 g/kg, UUO + SQP 3 g/kg, and UUO + SQP 6 g/kg groups. After treatment with SQP for 4 weeks, the appearance of kidney, serum creatinine (SCr), and blood urea nitrogen (BUN) levels were monitored in each group. The pathological injury, extracellular matrix (ECM), and Notch1 pathway-related protein levels were measured using H&E staining, Masson staining, immunohistochemistry, and Western blot, respectively.
SQP could obviously ameliorate the appearance of the kidney as well as the levels of SCr and BUN in UUO rats (SCr: 67.6 ± 4.64 μM, 59.66 ± 4.96 μM, 48.76 ± 4.44 μM, 40.43 ± 3.02 μM for UUO, low, medium, and high SQP treatment groups; BUN: 9.09 ± 0.97 mM, 7.72 ± 0.61 mM, 5.42 ± 0.42 mM, 4.24 ± 0.34 mM for UUO, low, medium, and high SQP treatment groups; P < .05). SQP also effectively mitigated renal tissue injury in UUO rats (P < .05). Moreover, we uncovered that SQP significantly inhibited Collagen I, α-SMA, Collagen IV, TGF-B1, Notch1, and Jag1 protein expressions in UUO rats kidney (P < .05).
Our data elucidated that SQP can alleviate RIF, and the mechanism may be related to the Notch1/Jag1 pathway. DOI: 10.52547/ijkd.7703.
摘要：
背景：肾气丸（SQP）可用于治疗各种肾脏相关疾病，但其确切的作用机制尚不清楚。我们旨在分析SQP在肾间质纤维化（RIF）中的作用和机制。
方法：按照机构动物护理和使用委员会指南进行单侧输尿管梗阻（UUO）手术后，所有大鼠被分配到假手术组，UUO组,UUO+SQP1.5g/kg,UUO+SQP3g/kg，和UUO+SQP6g/kg组。SQP治疗4周后,肾脏的外观，血清肌酐（SCr），监测各组血尿素氮(BUN)水平。病理损伤，细胞外基质（ECM），和Notch1通路相关蛋白水平使用H&E染色测量，Masson染色,免疫组织化学，和蛋白质印迹,分别。
结果：SQP可以明显改善UUO大鼠的肾脏外观以及SCr和BUN水平（SCr：67.6±4.64μM，59.66±4.96μM,48.76±4.44μM,UUO为40.43±3.02μM，低,中等,和高SQP治疗组；BUN：9.09±0.97mM，7.72±0.61mM，5.42±0.42mM，4.24±0.34mM对于UUO，低,中等,和高SQP治疗组；P<.05）。SQP还能有效减轻UUO大鼠肾组织损伤(P<0.05)。此外，我们发现SQP显著抑制胶原蛋白I，α-SMA,胶原蛋白IV,TGF-B1、Notch1和Jag1蛋白在UUO大鼠肾脏中的表达(P<0.05)。
结论：我们的数据阐明SQP可以缓解RIF，其机制可能与Notch1/Jag1通路有关。DOI:10.52547/ijkd.7703。
方法：按照机构动物护理和使用委员会指南进行单侧输尿管梗阻（UUO）手术后，所有大鼠被分配到假手术组，UUO组,UUO+SQP1.5g/kg,UUO+SQP3g/kg，和UUO+SQP6g/kg组。SQP治疗4周后,肾脏的外观，血清肌酐（SCr），监测各组血尿素氮(BUN)水平。病理损伤，细胞外基质（ECM），和Notch1通路相关蛋白水平使用H&E染色测量，Masson染色,免疫组织化学，和蛋白质印迹,分别。
结果：SQP可以明显改善UUO大鼠的肾脏外观以及SCr和BUN水平（SCr：67.6±4.64μM，59.66±4.96μM,48.76±4.44μM,UUO为40.43±3.02μM，低,中等,和高SQP治疗组；BUN：9.09±0.97mM，7.72±0.61mM，5.42±0.42mM，4.24±0.34mM对于UUO，低,中等,和高SQP治疗组；P<.05）。SQP还能有效减轻UUO大鼠肾组织损伤(P<0.05)。此外，我们发现SQP显著抑制胶原蛋白I，α-SMA,胶原蛋白IV,TGF-B1、Notch1和Jag1蛋白在UUO大鼠肾脏中的表达(P<0.05)。
结论：我们的数据阐明SQP可以缓解RIF，其机制可能与Notch1/Jag1通路有关。DOI:10.52547/ijkd.7703。
